DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time. The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during the confere ...

Core Viewpoint - Pelthos Therapeutics has acquired U.S. commercialization rights to Xepi® (ozenoxacin) Cream, a topical treatment for impetigo, marking a significant step in addressing unmet patient needs in pediatric dermatology [1][4][8] Acquisition Details - Pelthos will pay a total of $4.2 million upfront for the acquisition, consisting of $3.0 million to Biofrontera and $1.2 million to Ferrer, with additional payments tied to commercial availability and sales milestones [3][4] - The acquisition is expected to enhance Pelthos's portfolio, which is anchored by its existing product ZELSUVMI™ [8][10] Market Context - Impetigo affects approximately 3 million people annually in the U.S., predominantly children aged 2 to 5, highlighting a significant market opportunity for Xepi [5][8] - The rise of bacterial resistance to common topical antibiotics has created a pressing need for effective alternatives, positioning Xepi as a critical treatment option [6][8] Financing Details - Pelthos has secured $18 million through private convertible notes financing, which will support the acquisition and re-launch of Xepi, as well as the commercialization of ZELSUVMI [2][7][9] - The notes will bear an interest rate of 8.5% per annum and are convertible at an initial price of $34.442 [7][10] Strategic Implications - The acquisition and financing are seen as strategic moves to bolster Pelthos's commercial growth and leverage its existing infrastructure to promote multiple innovative brands [4][10] - The company plans to re-launch Xepi in late 2026, aiming to provide a novel treatment option in the pediatric dermatology space [4][8]

Core Viewpoint - Pelthos Therapeutics has acquired U.S. commercialization rights to Xepi® (ozenoxacin) Cream, a topical treatment for impetigo, marking a significant step in addressing unmet patient needs in pediatric dermatology [1][4][8] Acquisition Details - Pelthos will pay a total of $4.2 million upfront for the acquisition, consisting of $3.0 million to Biofrontera and $1.2 million to Ferrer, with additional payments tied to commercial availability and sales milestones [3] - The acquisition is expected to enhance Pelthos's portfolio, which is anchored by its existing product ZELSUVMI™ [8] Market Context - Impetigo affects approximately 3 million people annually in the U.S., predominantly children aged 2 to 5, highlighting a significant market opportunity for Xepi [5][8] - The need for effective alternatives to traditional treatments is underscored by rising bacterial resistance, particularly to commonly used topical antibiotics [6] Financing Details - Pelthos has secured $18 million through private convertible notes financing, which will support the acquisition and re-launch of Xepi, as well as the commercialization of ZELSUVMI [2][7][10] - The notes will bear an interest rate of 8.5% per annum and are convertible at an initial price of $34.442 [7] Strategic Implications - The acquisition of Xepi is seen as a strategic move to leverage Pelthos's existing commercial infrastructure and expand its product offerings in the pediatric and dermatology markets [4][10] - The company aims to re-launch Xepi in late 2026, positioning it as a critical treatment option amid growing concerns over antibiotic resistance [4][8]